Skip to main content
    B

    Becton Dickinson and Company (BDX)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NYSE

    $216.50
    -1.53 (-0.70%)

    Market Cap: $59.39B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Becton Dickinson and Company (BDX) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Becton Dickinson and Company (BDX) is expected to report earnings on Feb 8, 2027. In the quarter ended Sep 30, 2026, Becton Dickinson and Company reported EPS of $4.15, above the $4.06 estimate. It beat the EPS estimate in each of the last 12 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    90%(36/40)
    Avg Surprise
    +6.08%
    Streak
    12 Q

    Upcoming Estimates

    Reports Feb 8, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$2.35
    Range$2.34 - $2.37
    11 analysts
    EPS Estimate DriftChange to current
    90d ago$2.73-13.8%
    60d ago$2.73-13.9%
    30d ago$2.74-14.2%
    7d ago$2.73-13.9%
    Current$2.35
    Revenue Consensus
    $4.50B
    Range$4.46B - $4.57B
    10 analysts
    Report date not yet scheduledPeriod ending Mar 31, 2027
    EPS Consensus$3.03
    Range$2.96 - $3.14
    11 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$3.06-1.1%
    60d ago$3.05-0.8%
    30d ago$3.05-0.6%
    7d ago$3.05-0.6%
    Current$3.03
    Revenue Consensus
    $4.79B
    Range$4.76B - $4.83B
    10 analysts

    Next Report

    BDX has an expected report date of Feb 8, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 19.2% below the $2.91 reported for the quarter ended Dec 31, 2025.

    BDX Earnings Call

    The latest BDX earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, BDX beat 36, missed 1 and matched 3. The widest gap in the table came in the quarter ended Dec 31, 2020, when EPS landed 43.99% above the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$4.15$4.06$4.03 - $4.12+2.22%Beat+4.8%14N/ANov 5, 2026N/A
    Jun 30, 2026$3.23$3.14$3.06 - $3.19+2.87%Beat-12.2%129 up, 2 downAug 6, 2026$4.98B
    Mar 31, 2026$2.90$2.77$2.76 - $2.80+4.69%Beat-13.4%12N/AMay 7, 2026$4.71B
    Dec 31, 2025$2.91$2.80$2.79 - $2.85+3.93%Beat-15.2%101 up, 0 downFeb 9, 2026$5.25B
    Sep 30, 2025$3.96$3.91$3.87 - $3.95+1.28%Beat+3.9%110 up, 0 downNov 6, 2025$7.47B
    Jun 30, 2025$3.68$3.42$3.35 - $3.50+7.60%Beat+5.1%110 up, 4 downAug 7, 2025$4.73B
    Mar 31, 2025$3.35$3.28$3.22 - $3.31+2.13%Beat+5.7%122 up, 0 downMay 1, 2025$4.48B
    Dec 31, 2024$3.43$2.99$2.90 - $3.13+14.72%Beat+28.0%120 up, 1 downFeb 5, 2025$5.17B
    Sep 30, 2024$3.81$3.77$3.74 - $3.83+1.06%Beat+11.4%141 up, 0 downNov 7, 2024$5.44B
    Jun 30, 2024$3.50$3.31$3.27 - $3.37+5.74%Beat+18.2%140 up, 0 downAug 1, 2024$4.99B
    Mar 31, 2024$3.17$2.97$2.92 - $3.02+6.73%Beat+10.8%131 up, 0 downMay 2, 2024$5.04B
    Dec 31, 2023$2.68$2.40$2.37 - $2.48+11.67%Beat-10.1%120 up, 0 downFeb 1, 2024$4.71B
    Sep 30, 2023$3.42$3.43$3.32 - $3.52-0.29%Miss+24.4%130 up, 1 downNov 9, 2023$5.09B
    Jun 30, 2023$2.96$2.91$2.86 - $3.00+1.72%Beat+11.3%143 up, 0 downAug 3, 2023$4.88B
    Mar 31, 2023$2.86$2.75$2.70 - $2.78+4.00%Beat-10.1%130 up, 0 downMay 4, 2023$4.82B
    Dec 31, 2022$2.98$2.68$2.57 - $2.80+11.19%Beat-18.1%131 up, 0 downFeb 2, 2023$4.59B
    Sep 30, 2022$2.75$2.74$2.69 - $2.85+0.36%Beat+6.2%140 up, 1 downNov 10, 2022$4.76B
    Jun 30, 2022$2.66$2.50$2.45 - $2.58+6.40%Beat-2.9%131 up, 0 downAug 4, 2022$4.64B
    Mar 31, 2022$3.18$2.95$2.75 - $3.12+7.80%Beat-0.3%140 up, 0 downMay 5, 2022$4.75B
    Dec 31, 2021$3.64$2.85$2.59 - $3.04+27.72%Beat-20.0%14N/AFeb 3, 2022$4.72B
    Sep 30, 2021$2.59$2.45$2.38 - $2.75+5.71%Beat-7.2%16N/ANov 4, 2021$4.30B
    Jun 30, 2021$2.74$2.44$2.36 - $2.75+12.30%Beat+24.5%15N/AAug 5, 2021$4.61B
    Mar 31, 2021$3.19$3.04$2.88 - $3.17+4.93%Beat+25.1%16N/AMay 6, 2021$4.91B
    Dec 31, 2020$4.55$3.16$2.77 - $3.51+43.99%Beat+71.7%15N/AFeb 4, 2021$5.32B
    Sep 30, 2020$2.79$2.54$2.40 - $2.70+9.84%Beat-15.7%16N/ANov 5, 2020$3.74B
    Jun 30, 2020$2.20$2.07$1.69 - $2.35+6.28%Beat-28.6%16N/AAug 6, 2020$3.85B
    Mar 31, 2020$2.55$2.29$2.09 - $2.49+11.35%Beat-1.5%15N/AMay 7, 2020$4.25B
    Dec 31, 2019$2.65$2.64$2.57 - $2.70+0.38%Beat-1.9%15N/AFeb 6, 2020$4.22B
    Sep 30, 2019$3.31$3.31$3.28 - $3.340.00%In line+13.0%16N/ANov 5, 2019$4.58B
    Jun 30, 2019$3.08$3.06$2.96 - $3.22+0.65%Beat+5.8%18N/AAug 6, 2019$4.35B
    Mar 31, 2019$2.59$2.59$2.53 - $2.620.00%In line-2.3%19N/AMay 9, 2019$4.20B
    Dec 31, 2018$2.70$2.62$2.50 - $2.80+3.05%Beat+8.9%20N/AFeb 5, 2019$4.16B
    Sep 30, 2018$2.93$2.93$2.89 - $2.980.00%In line+22.1%18N/ANov 6, 2018$4.40B
    Jun 30, 2018$2.91$2.86$2.79 - $2.95+1.75%Beat+18.3%17N/AAug 2, 2018$4.28B
    Mar 31, 2018$2.65$2.63$2.54 - $2.70+0.76%Beat+15.2%18N/AMay 3, 2018$4.22B
    Dec 31, 2017$2.48$2.41$2.26 - $2.59+2.90%Beat+6.4%18N/AFeb 6, 2018$3.08B
    Sep 30, 2017$2.40$2.37$2.32 - $2.40+1.27%Beat+13.2%15N/ANov 2, 2017$3.17B
    Jun 30, 2017$2.46$2.44$2.38 - $2.53+0.82%Beat+4.7%15N/AAug 3, 2017$3.04B
    Mar 31, 2017$2.30$2.23N/A+3.14%Beat+5.5%N/AN/AMay 2, 2017$2.97B
    Dec 31, 2016$2.33$2.11N/A+10.43%Beat+18.9%N/AN/AFeb 2, 2017$2.92B
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Sep 30, 2026 was $13.19, down 8.5% from the year before. It was $9.49 for the year ended Sep 30, 2017, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Sep 30, 2026$13.19-8.5%
    Sep 30, 2025$14.42+9.6%
    Sep 30, 2024$13.16+7.7%
    Sep 30, 2023$12.22N/A
    Sep 30, 2022$12.23-6.4%
    Sep 30, 2021$13.07+28.3%
    Sep 30, 2020$10.19-12.8%
    Sep 30, 2019$11.68+6.5%
    Sep 30, 2018$10.97+15.6%
    Sep 30, 2017$9.49N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,100 words across 13 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20267,13713
    2026Q2Jun 30, 20266,45614
    2026Q1Mar 31, 20268,36414
    2025Q4Dec 31, 20257,1989
    2025Q3Sep 30, 20255,0808
    2025Q2Jun 30, 20256,96212
    2025Q1Mar 31, 20257,48113
    2024Q4Dec 31, 20247,07714

    2026Q3 Earnings Call

    Opening remarks

    Shawn Bevec Senior Vice President, Investor Relations Good morning, and welcome to BD's earnings call. I'm Shawn Bevec, Senior Vice President of Investor Relations. Thank you for joining us. This call is being made available via audio webcast at bd.com. Earlier this morning, BD released its results for the third quarter of fiscal 2026. The press release and presentation can be accessed on the IR website at investors.bd.com. Leading today's call are Tom Polen, BD's Chairman, Chief Executive Officer and President; and Vitor Roque, Executive Vice President and Chief Financial Officer. Before we get started, I want to remind you that we will be making forward-looking statements. You can read the disclaimer in our earnings release and the disclosures in our SEC filings on our Investor Relations website. Unless otherwise specified, all comparisons will be made on a year-on-year basis versus the relevant fiscal period. Revenue percentage changes are on an FX-neutral basis unless otherwise noted. Also, references to adjusted EPS refer to adjusted diluted EPS. Financials discussed here and included in the earnings release and 10-Q are presented on a continuing operations basis. Prior periods have been recast to reflect the spin-off of our Life Sciences business in combination with Waters, which is now accounted for as discontinued operations. Reconciliations between GAAP and non-GAAP measures are included in the appendices of the earnings release and presentation. With that, I will turn it over to Tom.

    Thomas Polen Chairman, Chief Executive Officer and President Thank you, Shawn, and good morning, everyone. We delivered a strong third quarter with revenue, adjusted operating margin and adjusted EPS all ahead of our expectations. This was our first full quarter operating as New BD. And more importantly, the quality of this performance reflects our more focused portfolio beginning to demonstrate the growth and earnings potential we designed it to deliver. Performance was broad-based, reflecting commercial momentum across our key growth platforms, strong operational execution and the expanding impact of BD Excellence. Revenue was $5 billion, up 4.4% with more than 90% of the portfolio delivering high single-digit growth. Performance continues to be driven by ongoing structural improvements across our key growth platforms, where we've been focused on enhancing commercial execution and driving product innovation. This includes double-digit growth across biologic drug delivery, advanced patient monitoring, PureWick and advanced tissue regeneration, along with strong performance in peripheral vascular disease and Rowa pharmacy automation. As these platforms continue to scale and growth outpaces the broader portfolio, they are becoming more meaningful drivers of top and bottom line performance. We also saw strong U.S. performance in MDS and specimen management, driven by broad underlying utilization as well as share gains.

    Frequently Asked Questions About BDX

    When is Becton Dickinson and Company's next earnings date?

    Becton Dickinson and Company's next earnings report is expected for Feb 8, 2027.

    Did BDX beat earnings estimates last quarter?

    Yes. Becton Dickinson and Company reported EPS of $4.15 for the quarter ended Sep 30, 2026, above the $4.06 estimate, a 2.22% surprise.

    What EPS do analysts expect from BDX next quarter?

    The consensus EPS estimate for Becton Dickinson and Company for the quarter ending Dec 31, 2026 is $2.35 from 11 analysts, with estimates from $2.34 to $2.37.

    How often does BDX beat earnings estimates?

    Becton Dickinson and Company beat the EPS estimate in each of the last 12 quarters, with an average surprise of +5.39%.